Ophthalmology Department,Tokat State Hospital, Turkey.
Curr Eye Res. 2011 Nov;36(11):1005-13. doi: 10.3109/02713683.2011.601840.
To investigate the inhibitory effect of subconjunctival application of VEGF antibodies bevacizumab, ranibizumab, pegaptanib, and HER2 antibody trastuzumab on corneal neovascularization in a rat model of experimental corneal neovascularization.
Thirty male Wistar albino rats were included in the study. A chemical burn was induced in central cornea of one eye of the rats by a 75% silver nitrate and 25% potassium nitrate stick. Rats were randomly divided into five groups so that each group contained 6 subjects. Right after the chemical burn, 0.1 ml serum physiologic was injected subconjuctivally in control group (group 1). 1.25 mg/0.05 ml bevacizumab was injected in group 2; 1.2 mg/0.1 ml trastuzumab was injected in group 3; 0.5 mg/0.05 ml ranibizumab was injected in group-4; and 0.3 mg/0.1 ml pegaptanib was injected in group 5. On the 8th day of the experiment, rat corneas were photographed by digital photo-camera. Later, eyes of the sacrificed rats were enucleated and corneal speciements were histopathologically analyzed. The percentages of neovascularization on corneal photographs were examined with digital image analysis.
The percentage of corneal neovascularization in all treatment groups was found to be significantly lower than the control group (p < 0.05). Bevacizumab was found to be more effective than all other agents (p < 0.05). While the degree of inflammation and vascularization in bevacizumab and trastuzumab groups were significantly lower than the control group (p < 0.05), the difference was not significant in ranibizumab and pegaptanib groups (p > 0.05). In all treatment groups, fibroblast intensity was significantly lower than the control group. In terms of corneal thickness, no significant difference was observed between treatment and control groups (p > 0.05).
Bevacizumab, ranibizumab, pegaptanib, and trastuzumab were found effective for the inhibition of corneal NV. In our study we detected that the most effective agent was bevacizumab.
研究玻璃体内应用抗血管内皮生长因子抗体贝伐单抗、雷珠单抗、聚乙二醇化阿柏西普和曲妥珠单抗对实验性角膜新生血管大鼠模型角膜新生血管的抑制作用。
将 30 只雄性 Wistar 白化大鼠纳入研究。用 75%硝酸银和 25%硝酸钾棒在大鼠中央角膜诱导化学烧伤。大鼠随机分为五组，每组 6 只。在对照组（第 1 组），于化学烧伤后立即向结膜下注射 0.1ml 生理盐水。第 2 组注射 1.25mg/0.05ml 贝伐单抗；第 3 组注射 1.2mg/0.1ml 曲妥珠单抗；第 4 组注射 0.5mg/0.05ml 雷珠单抗；第 5 组注射 0.3mg/0.1ml 聚乙二醇化阿柏西普。实验第 8 天，用数码照相机构拍大鼠角膜照片。之后，处死大鼠并取出眼球，进行角膜组织病理学分析。用数码图像分析检查角膜照片上的新生血管百分比。
所有治疗组的角膜新生血管百分比均明显低于对照组（p<0.05）。贝伐单抗的效果优于其他所有药物（p<0.05）。贝伐单抗和曲妥珠单抗组的炎症和血管化程度明显低于对照组（p<0.05），而雷珠单抗和聚乙二醇化阿柏西普组无显著差异（p>0.05）。在所有治疗组中，成纤维细胞强度明显低于对照组。在角膜厚度方面，治疗组与对照组无显著差异（p>0.05）。
贝伐单抗、雷珠单抗、聚乙二醇化阿柏西普和曲妥珠单抗对抑制角膜 NV 有效。在我们的研究中，我们发现最有效的药物是贝伐单抗。
